Evidence map›Paper›PMID 40370541›Full record

ArticleActa pharmaceutica Sinica. B2025

Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment.

Lauren C Naatz, Shuyun Dong, Brian Evavold, Xiangyang Ye, Mingnan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lauren C NaatzDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
Shuyun DongDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
Brian EvavoldDepartment of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
Xiangyang YeDepartment of Pharmacotherapy, University of Utah, Salt Lake City, UT 84112, USA.
Mingnan ChenDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.

Funding

Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunityR01AI139535 · NIAID · UNIVERSITY OF UTAH · PI CHEN, MINGNAN · 2019 to 2024
$2.7M
The Neuroimmunology Training Program at the University of UtahT32NS115664 · NINDS · UNIVERSITY OF UTAH · PI O'CONNELL, RYAN M, WILCOX, KAREN S · 2020 to 2024
$988k
PD-1 BiKE: Targeting and Depleting PD-1 Positive Cells for Autoimmune Disease TreatmentR21AI185716 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI CHEN, MINGNAN · 2025 to 2025
$424k
NIAID NIH HHS R01 AI139535NIAID NIH HHS R21 AI185716NINDS NIH HHS T32 NS115664
6 · The paper itself

Abstract

Bispecific killer cell engagers (BiKEs) are a powerful tool to incite the killing power of natural killer (NK) cells. Here, we posited that the BiKE technology could be utilized to deplete activated immune cells expressing programmed death-1 (PD-1

Indexed as

Antibody-dependent cellular cytotoxicityAutoimmune diseaseBispecific antibodyBispecific killer engagerImmunotherapyNatural killer cellPD-1PD-1-positive cells

Identifiers

PMID40370541
PMCPMC12069113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.